Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3561
+0.0072 (+2.06%)
Official Closing Price
Updated: 8:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
November 15, 2021
Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited...
Via
Benzinga
Exposures
Product Safety
Cybin Releases Q2 Financial Results
November 15, 2021
Cybin (NYSE:
Via
Benzinga
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
November 14, 2021
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.
Via
Talk Markets
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
November 14, 2021
This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used t...
Via
Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'
November 11, 2021
This article was originally published on
Via
Benzinga
Cybin to Release Q2 2021 Results on November 15
November 09, 2021
Cybin (NYSE:
Via
Benzinga
Cybin Inc. Receives Schedule I Manufacturing License from DEA
November 04, 2021
Cybin (NYSE:
Via
Benzinga
Cybin CEO Presenting at Jefferies London Healthcare Conference
November 11, 2021
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the...
Via
Benzinga
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
November 09, 2021
Shares plunged, despite a psilocybin-based drug reducing depression in a trial.
Via
Investor's Business Daily
32 Stocks Moving in Tuesday's Pre-Market Session
November 09, 2021
Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after...
Via
Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
November 08, 2021
Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive...
Via
Benzinga
64 Biggest Movers From Yesterday
November 09, 2021
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile...
Via
Benzinga
Cybin's CYB003 Demonstrates Advantages over Oral Psilocybin for Mental Health
November 08, 2021
Cybin (NYSE:
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
Detroit Decriminalizes Psychedelics
Via
Benzinga
Exposures
Product Safety
Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules
November 04, 2021
Cybin Inc. (NYSE:CYBN) a company developing novel psychedeli...
Via
Benzinga
Cybin Inc. Schedules R&D Briefing to Release Breakthrough Research Findings
November 02, 2021
Cybin (NEO: CYBN) (NYSE:
Via
Benzinga
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
November 01, 2021
The Week In Psychedelics:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
October 27, 2021
Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)...
Via
Benzinga
Exposures
Product Safety
Cybin Inc. Announces FDA IND Authorization of Potentially Pivotal Study
October 27, 2021
Cybin (NYSE:
Via
Benzinga
Exposures
Product Safety
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
The Week In Psychedelics
Via
Benzinga
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
October 23, 2021
The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last.
Via
Talk Markets
Psychedelics Discussed At Benzinga Cannabis Capital Conference: Growth Opportunities, Mental Health & Pharma
October 19, 2021
Ronan Levy, co-founder and executive chairman of Field Trip Ltd (NASDAQ: FTRP), a company developing a network of psychedelics-assisted therapy clinics; Doug Drysdale, CEO,...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
October 15, 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.
Via
Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments?
October 01, 2021
This article by Jason Najum was originally published on
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
October 05, 2021
Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ:
Via
Benzinga
Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference
September 30, 2021
The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ...
Via
Benzinga
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?
September 21, 2021
We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses.
Via
Talk Markets
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.